香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Medtide Inc. 泰 德 醫 藥（ 浙 江 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3880） 建議修訂本公司章程及取消監事會 泰德醫藥（浙江）股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，於2026年3月30日，董事會通過有關（其中包括）建議修訂本公司章程及取消 監事會的決議案。 建議修訂本公司章程及取消監事會 於2023年12月29日，《中華人民共和國公司法》（「中國公司法」）修訂案獲採納， 自2024年7月1日起生效。新中國公司法引入的修訂包括但不限於改革公司資本制 度及組織機構設置、加強對少數股東權益的保護、強化控股股東、董事及高級管 理人員的責任，以及允許以審核委員會取代監事會。為確保上市公司能有效遵守 及實施中國公司法的新規定，中國證券監督管理委員會於2025年3月28日發佈了 多份重要文件，包括經修訂的《上市公司章程指 ...

Financial Performance - Revenue increased by 28.9% to RMB 570.1 million for the year ended December 31, 2025, compared to RMB 442.2 million for the previous year[8] - Gross profit rose by 44.8% to RMB 361.6 million, with a gross margin of 63.4%, up from 56.5%[3] - Net profit surged by 267.3% to RMB 217.4 million, compared to RMB 59.2 million in the prior year, resulting in a net profit margin of 38.1%[8] - The adjusted net profit (non-IFRS measure) increased by 28.9% to RMB 221.7 million for the year ended December 31, 2025, from RMB 172.0 million in the previous year[8] - Revenue for the year ending December 31, 2025, was RMB 570.1 million, a 28.9% increase from RMB 442.2 million for the year ending December 31, 2024[27] - Revenue from FFS services was RMB 530.8 million, up 24.8% from RMB 425.3 million in the previous year[28] - Revenue from FTE services surged 137.3% to RMB 39.3 million from RMB 16.6 million year-over-year[29] - Revenue from CDMO services increased by 30.5% to RMB 430.6 million, driven by clients in late-stage clinical or commercial projects[31] - The net profit for the fiscal year ending December 31, 2025, was RMB 217.4 million, significantly up from RMB 59.2 million for the fiscal year ending December 31, 2024[42] - The adjusted net profit (non-IFRS measure) for the fiscal year ending December 31, 2025, was RMB 221.7 million, compared to RMB 172.0 million for the fiscal year ending December 31, 2024[45] Operational Growth - The number of ongoing projects at year-end increased to 1,614, up from 1,549 in the previous year, with new projects acquired during the year totaling 9,446[6] - The workforce grew by 11.0% to 566 full-time employees as of December 31, 2025, compared to the previous year[5] - The company expanded its peptide production capacity with the installation of a new 3,000-liter SPPS reactor and a 50-inch purification column, significantly increasing commercial scale production capacity to over 1 ton[5] - The company is actively expanding its facilities to meet the growing demand for TIDES CRDMO services globally[5] - The expansion project in Qiantang Park is nearing completion, with new large-scale equipment including a 3,000-liter SPPS reactor to significantly increase commercial-scale peptide API production[20] Market and Product Development - The company is strategically expanding its business into Europe and other Asian markets while enhancing its capabilities in the oligonucleotide therapeutic market[21] - The company is involved in the development of peptide-based drugs and oligonucleotide drugs, which are key components of its product offerings[105] - The company is actively engaged in the development of new chemical entities (NCEs) that are currently undergoing clinical trials[104] - The company is exploring market expansion opportunities in regions governed by regulatory bodies such as the FDA and EMA[103] - The global peptide drug market is expected to grow from $89.5 billion in 2023 to $261.2 billion by 2032, with a compound annual growth rate (CAGR) of 12.6%[24] - The GLP-1 sector is projected to expand from $38.9 billion to $129.9 billion, reflecting a CAGR of 14.3%[24] Compliance and Certifications - The company received ISO 22716:2007 certification for good manufacturing practices in cosmetics in January 2025 and obtained approval for the marketing of the API of Acetate Gosserelin in March 2025[5] - The company has received ISO9001 and ISO13485 certifications, ensuring compliance with international quality standards[19] - The company has a strong emphasis on compliance with regulatory standards such as GLP and GMP to ensure product quality and safety[103] Financial Position and Risks - As of December 31, 2025, the company had cash and cash equivalents of RMB 887.6 million, up from RMB 387.2 million as of December 31, 2024[46] - The debt-to-asset ratio as of December 31, 2025, was 12.6%, a significant decrease from 72.8% as of December 31, 2024[51] - The company has not used any financial instruments for hedging purposes as of December 31, 2025, exposing it to foreign exchange risks primarily related to USD, HKD, and EUR[54] - The management will continue to monitor foreign exchange risks and consider using appropriate derivatives when necessary[55] Corporate Governance - The company has committed to maintaining high standards of corporate governance since its listing on June 30, 2025[90] - The company has adopted a code of conduct for securities trading by directors and supervisors, ensuring compliance since the listing date[92] - The company plans to continue regular reviews of its corporate governance practices to ensure adherence to the corporate governance code[91] - The audit committee reviewed the consolidated financial statements for the year ending December 31, 2025, confirming compliance with applicable accounting standards and regulations[94] Research and Development - The company has a strong focus on R&D, with 66 employees in the department, approximately 40% holding a master's degree or higher, to enhance technical capabilities[15] - The company utilizes advanced synthesis methods like SPPS for efficient production of complex peptide sequences[104] - The company is leveraging its expertise in peptide synthesis to innovate in the field of drug development and delivery[104] - The company is focused on enhancing its product portfolio with new technologies and research initiatives in the biopharmaceutical space[105]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Medtide Inc. 泰 德 醫 藥（ 浙 江 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3880） 董事會會議召開日期 泰德醫藥（浙江）股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會 會議將於2026年3月30日（星期一）召開，藉以（其中包括）審議及批准本公司及其 附屬公司截至2025年12月31日止年度的年度業績及其刊發，並考慮派發末期股息 之建議（如有）以及處理其他事項。 承董事會命 泰德醫藥（浙江）股份有限公司 董事長兼首席執行官 徐琪博士 香港，2026年3月16日 於本公告日期，本公司執行董事為徐琪博士、李湘博士、李湘莉女士、Cheng Tao 女士及李玲梅女士；本公司非執行董事為吳一暉先生；及本公司獨立非執行董事 為于常海博士、朱迅博士及夏心晟先生。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期： 2026年3月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | H 股份類別 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) 03880 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | 佔有關事件前的現有已發 已發行股份（不包括庫存股份）數 行股份（不包括庫存股 目 份）數目百分比 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Medtide Inc. 泰 德 醫 藥（ 浙 江 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3880） 內幕消息 完成H股全流通 本公告乃由泰德醫藥（浙江）股份有限公司（「本公司」）根據香港聯合交易所有限公 司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章《證 券及期貨條例》第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 茲提述(i)本公司日期為2025年7月27日的公告，內容有關本公司H股全流通的申 請；及(ii)本公司日期為2026年2月5日的公告，內容有關中國證監會就本公司H股 全流通申請發出備案通知書（統稱「該等公告」）。除非另有說明，本公告所用詞彙 與該等公告所界定者具有相同涵義。 1 股權結構 本公司於緊接轉換及上市完成前及完成後的股權結構如下： | | 於本公告日期 | | 於轉換及上市完成後 | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 第 1 頁 共 11 頁 v 1.2.0 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 2 ...

Core Viewpoint - Tedd Medical (03880) has experienced a significant stock price increase, reflecting positive market sentiment following its revenue and profit forecasts for the fiscal year ending December 31, 2025 [1][3]. Financial Performance Summary - The company anticipates revenue between RMB 555 million and RMB 585 million, representing a year-on-year increase of approximately 25.5% to 32.3% [1][3]. - Profit is expected to be between RMB 200 million and RMB 230 million, indicating a substantial year-on-year increase of approximately 237.8% to 288.5% [1][3]. Market Reaction - Tedd Medical's stock price rose over 6% during trading, with a current price of HKD 26.60 and a trading volume of HKD 2.1157 million [1][3].

Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong market demand in the peptide sector [1] Financial Performance - The expected revenue for 泰德医药 is projected to be between RMB 5.55 billion and RMB 5.85 billion, representing a year-on-year increase of approximately 25.5% to 32.3% [1] - The anticipated profit is estimated to be between RMB 2 billion and RMB 2.3 billion, indicating a substantial year-on-year increase of approximately 237.8% to 288.5% [1] Strategic Factors - Revenue growth is attributed to the successful execution of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] - The company highlights its industry-leading project delivery timeliness and excellent project execution track record as key contributors to its performance [1] - There is a strong and growing demand from key clients for the company's services, driven by advancements in its research and development pipeline and the rapid expansion of the global peptide market, particularly in the GLP-1 sector [1]

Core Viewpoint - The company, 泰德医药, anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by strategic initiatives and strong market demand in the peptide sector [1] Group 1: Financial Projections - The expected revenue for 泰德医药 is approximately RMB 5.55 billion to 5.85 billion, representing a year-on-year increase of about 25.5% to 32.3% [1] - The projected profit is estimated to be between RMB 2 billion and 2.3 billion, indicating a substantial year-on-year increase of approximately 237.8% to 288.5% [1] Group 2: Growth Drivers - Revenue growth is attributed to the successful implementation of the "follow-on molecule" strategy and the advantages of the integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform [1] - The company has demonstrated industry-leading project delivery timeliness and excellent project execution track record, which has led to strong demand from key clients [1] - The expansion of the global peptide market, particularly in the glucagon-like peptide-1 (GLP-1) sector, is a significant factor contributing to the company's growth [1]

Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market [1] Financial Projections - The projected revenue for the fiscal year ending December 31, 2025, is approximately RMB 5.55 billion to RMB 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of RMB 4.42 billion for the fiscal year ending December 31, 2024 [1] - The expected profit for the fiscal year ending December 31, 2025, is around RMB 2 billion to RMB 2.3 billion, which marks an increase of approximately 237.8% to 288.5% from the estimated profit of RMB 592 million for the fiscal year ending December 31, 2024 [1] - The adjusted net profit (non-IFRS measure) for the fiscal year ending December 31, 2025, is projected to be about RMB 2 billion to RMB 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% compared to the adjusted net profit of RMB 1.72 billion for the fiscal year ending December 31, 2024 [1] Growth Drivers - Revenue growth is primarily attributed to the successful implementation of the "follow-on molecule" strategy, the advantages of the company's integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform, and the strong demand from key clients due to advancements in their R&D pipelines [1] - The rapid expansion of the global peptide market, particularly in the glucagon-like peptide-1 (GLP-1) sector, is also a significant factor contributing to the anticipated growth [1]